What question did this study set out to answer?

The review aims to explore the causes and solutions for secondary poor graft function after autologous stem cell transplantation in multiple myeloma.

February 25, 2026

Secondary poor graft function after autologous stem cell transplantation in multiple myeloma: a case-based expert review and successful rescue with secondary autologous stem cell infusion.

Key Points

The review aims to explore the causes and solutions for secondary poor graft function after autologous stem cell transplantation in multiple myeloma.
Expert analysis of case reports on secondary PGF after Auto-HSCT.
Identification of factors contributing to PGF and assessment of potential interventions.
Evaluation of the efficacy of secondary autologous PBSC infusion as a rescue strategy.
Identified multiple factors causing secondary poor graft function, including graft quality issues and therapy exposure.
Early unpreconditioned autologous PBSC boost found to be safe and feasible.
Strategic banking of PBSC identified as crucial for preventing life-threatening graft failures.

Abstract

Secondary PGF after Auto-HSCT appears multifactorial, involving quantitatively adequate but qualitatively fragile grafts, inflammatory/microenvironmental injury, and therapy-related megakaryocytic vulnerability (including heavy lenalidomide exposure). When backup cells are available and reversible causes are excluded, early unpreconditioned autologous PBSC boost is a safe, feasible, and likely under-utilized salvage strategy. Strategic PBSC banking and early recognition may prevent life-threatening PGF.

Bookmark

Cite This Study

You et al. (Tue,) studied this question.

synapsesocial.com/papers/699e9152f5123be5ed04ebfd https://doi.org/https://doi.org/10.1080/16078454.2026.2633462

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark